After the TGN1412 Tragedy: Addressing the Right Questions at the Right Time for Early Phase Testing

Carol Levine and Jeremy Sugarman

, 04/17/2006

After the TGN1412 Tragedy: Addressing the Right Questions at the Right Time for Early Phase Testing

(Research) Permanent link

Carol Levine and Jeremy Sugarman

Five of the six British men who suffered devastating illnesses after receiving an experimental compound - TGN1412 - in the first phase of human testing are now reported to be out of hospital, and the sixth is apparently out of intensive care. Although it is unclear whether they will suffer long-term health effects from this catastrophic experience, for now the news is mostly good.

The bad news is that this trial apparently went forward on a "business-as-usual" approach, and something like it could happen again. The basic problem is neither that the subjects were paid, nor that the research was not conducted at an academic medical institution. Paying research subjects for their time and inconvenience is accepted practice, although very high payments raise serious questions about "undue inducements" to participate. Furthermore, the three research subject deaths that caused so much concern in the United States in recent years occurred in trials conducted at well-respected, large academic centers - the University of Rochester, University of Pennsylvania, and Johns Hopkins University.

The basic problem in the TGN1412 study, as we see it, is that those involved ignored critical aspects of the research that should have warranted what we have called "special scrutiny." With our colleagues in the Consortium to Examine Clinical Research Ethics (CECRE), in a 2004 article in the Annals of Internal Medicine, we pointed out that traditional methods to protect research participants - such as informed consent and special protections for "vulnerable groups" - are necessary but have never been sufficient to protect participants' welfare.

In proposing a focused, special kind of scrutiny for research that raises serious moral issues, particularly in the new globalized, privatized research environment, we challenged institutional review boards, investigators, and sponsors to recognize and respond to the moral complexities of a protocol before it is implemented, not after it is criticized in the scientific or lay press - nor, we might have added, after subjects have already been harmed.

These are our criteria for special scrutiny:

Criterion 1. "The research involves initial experiences of translating new scientific advances to studies in humans, especially when the intervention is novel, irreversible, or both."

Criterion 2. "Without potential for offsetting direct medical benefit, there is a known or credible risk for significant harm (death or serious disability are the clearest examples) to humans as a consequence of the experimental intervention."

Criterion 3. "The protocol raises ethical questions about research design or implementation for which there is no consensus or there are conflicting or ambiguous guidelines."

Even based solely on information made publicly available from newspaper and journal reports, the TGN1412 trial appears to have met all three criteria for special scrutiny. Had it been subjected to that process, it might have never gone forward as it was designed and implemented. Some reports assert that it was initially rejected in Germany.

Here's what is publicly known: The TGN1412 study was the first test in humans of a new compound developed by a German company called TeGenero and manufactured by another German company, Boehringer Ingelheim. According to TeGenero's Web site, its "most advanced product candidate is TGN1412, a fully humanized CD28-SuperMAB®." This monoclonal antibody is designed to mobilize one part of the immune system specifically to attack another part. "TGN1412 is a promising novel approach," the company says, "to addressing the medical need in chronic autoimmune/inflammatory diseases, which require long-term therapy without severe side effects." In other words, if this compound works, it could have a huge market in treating devastating diseases such as rheumatoid arthritis and leukemia.

TeGenero did not conduct the clinical trial itself. That was a job for Parexel International, a Massachusetts-based major contract research organization (CRO), one of the intermediaries that now manage a great deal of clinical research in this country and abroad. Their responsibilities included obtaining ethical review of the protocol, which in this case was conducted by the Brent Medical Ethics Committee, a North London group that reviews protocols for National Health Service-sponsored trials in the Borough of Brent. It is authorized to review both Phase I (safety and toxicity trials) and Phase II trials (dosage and preliminary efficacy trials).

For routine protocols, which make up the bulk of clinical research, this kind of international, private-public collaboration is not particularly unusual and perhaps not worrisome. But someone at some point has to recognize that a particular protocol is not routine - indeed is highly unusual - and call for a more stringent and focused review.

For example, in this case the animal evidence required very careful review, since, according to one report, monkeys developed swelling of the immune tissue in their necks. TeGenero asserts that "TGN1412 had been tested extensively in laboratories and on rabbits and monkeys, with no adverse effects and no drug-related deaths." But in another statement it acknowledged that one animal (it is not clear whether it was a rabbit or monkey) "sadly had to be put down during the trial after suffering diarrhea caused by an unrelated bacterial infection."

Since the trial subjects were healthy - which is standard in phase I toxicity trials - there were no offsetting direct benefits to them; therefore, particular attention should have been paid to the potential risks of a compound designed to effect a major alteration of the human immune system. There was no reason - other than efficiency - to give the drug to all six subjects at approximately the same time, and in fact this approach is very unusual in first-in-human studies. By all available accounts, the first person to get the drug started having major symptoms (pain and swelling) almost immediately; yet there was apparently no delay in giving it to the others.

In its investigation the British Medicines and Healthcare Products Regulatory Agency (MHRA) found that there had been no deviation from the protocol or contamination of the drug, so the sequence of administration must have been in the protocol itself - a serious design flaw. Further, it remains unclear why two subjects were given placebo (the lucky ones, as it turned out), since the trial was not meant to determine efficacy. Nor could placebos be justified on the grounds that the subjects would likely have a confounding underlying condition that would make assessing safety difficult in those who received the experimental compound.

Finally, according to two ethicists who reviewed the 13-page consent form, the language was complex. The consent form did not make clear that this was a "first-in-humans" trial, and minimized the risks of altering the immune system. Reportedly the form stated that "No significant side effects had been seen in the animal studies," suggesting, perhaps, that there had been some side effects but that the company did not consider them "significant." There was also no information about who participants could contact at the ethics review committee should they have any questions during the trial.

It is easy to point to the profit motive as the source of the trouble, and this may have influenced the unusual study design. However, it is critical to acknowledge the important ways in which the research landscape has changed in the past few decades. There are now so many organizations and individuals involved that the connection between the participant and the researchers may be remote. Among the details missing from the accounts so far is the name of the principal investigator - the person who is ultimately responsible for the conduct of the trial. The only statements have come from corporate officials. No sponsor, CRO, or even ethics committee can take the place of an individual researcher who values participant safety and well-being above product development.

Even when the principal investigator is conscientious, however, others still have important responsibilities, which sometimes include asking hard questions that may delay or even stop a trial. So be it: the consequences for individual subjects and the research enterprise as a whole are momentous. Special scrutiny, as we have envisioned it, suggests the circumstances when heightened attention is warranted, which is not the case for all research. In fact, in assuming a "one size fits all" approach, the current oversight system sends inappropriate messages regarding its critical role. Clearly there is room for enhancing efficiency in the ethical review of some research, but first-in-human studies, such as that involving TGN1412, are not the place to start.

Posted by Greg Kaebnick at 04/17/2006 12:00:00 AM | 

I totally agree. Getting interaction into a blog post, helps the actual blog post gain more traction
Posted by: ( Email | Visit ) at 6/1/2014 11:33 AM

I really appreciate the info, thank you.
Posted by: ( Email | Visit ) at 7/23/2014 1:59 AM

I like it, I learned something today! Thanks!
Posted by: ( Email | Visit ) at 7/23/2014 2:02 AM

thanked for this info ..... :-)
Posted by: ( Email | Visit ) at 7/23/2014 2:05 AM

I agree with the comment of you. Thanks for share with us
Posted by: ( Email | Visit ) at 11/11/2014 12:05 AM

Thank you for the great article I did enjoyed reading it, I want to encourage that you continue your great job, have a good day.
Posted by: ( Email | Visit ) at 3/9/2015 3:15 AM

nice post
Posted by: ( Email | Visit ) at 4/6/2015 11:39 PM

Thank you for the great a
Posted by: ( Email | Visit ) at 4/6/2015 11:40 PM

Posted by: ( Email | Visit ) at 4/6/2015 11:42 PM

Posted by: ( Email | Visit ) at 4/6/2015 11:42 PM

Posted by: ( Email | Visit ) at 4/6/2015 11:43 PM

Posted by: ( Email | Visit ) at 4/6/2015 11:43 PM

Posted by: ( Email | Visit ) at 4/6/2015 11:43 PM

A reliable informative post thаt уоu hаve shared аnd apрrеcіatе уоur work fоr sharing thе information. Gоt somе entertaining information аnd wоuld likе tо provide іt а try. Applaud уоur work аnd kееp sharing yоur information.
Posted by: ( Email | Visit ) at 4/11/2015 12:29 AM

Thіs post іs amazing іn thе sense thаt іt hаs helped mе understand ѕomе оf thе mоѕt complex problems lіke thіѕ one. Thеѕе projects аre amazing аnd thеу саn bе usеd tо lеt thе public knоw hоw important іt iѕ fight thе energy crisis.
Posted by: ( Email | Visit ) at 4/11/2015 12:30 AM

Yоur website іѕ verу informative. It wіll bе uѕеful fоr аll оf us. Yоu havе completed а bеѕt work. I wіll соmе hеrе аgain tо analyze nеw updates. Thаnks fоr posting..I hаve read аll thе comments аnd suggestions posted bу thе visitors fоr thіѕ article arе vеrу good,We wіll wait fоr уour nеxt article soonly.Thanks!!
Posted by: ( Email | Visit ) at 4/11/2015 12:31 AM

I hаvе beеn іn loоk fоr оf ѕоme information abоut іt аlmoѕt threе time. Yоu served mе а lot іndeed аnd analyzing thіs уour publish I hаve fоund mаnу nеw аnd uѕеful information abоut thiѕ topic.
Posted by: ( Email | Visit ) at 4/11/2015 12:32 AM

Thіѕ iѕ оne оf thе good articles yоu сan find іn thе net explaining evеrуthіng іn detail regаrding thе topic. I thаnk уou fоr tаking yоur time sharing yоur thoughts аnd ideas tо а lot оf readers оut there.
Posted by: ( Email | Visit ) at 4/11/2015 12:38 AM

Whеn I fіrst visit thiѕ site аnd trу tо lоok whаt thіѕ site talks аbоut I waѕ reаlly amazed with.WOW!fantastic.You сould hаve gеt nеw important аnd interesting topic tо bе discuss. Rеallу feel great thаt I visit thiѕ site.
Posted by: ( Email | Visit ) at 4/11/2015 12:50 AM

A reliable informative post that you have shared and appreciate your work for sharing the information. Got some entertaining information and would like to provide it a try. Applaud your work and keep sharing your information.
Posted by: ( Email | Visit ) at 4/11/2015 12:56 AM

I reallу enjoyed thе quality information yоu offer tо уour visitors fоr thiѕ blog. I wіll bookmark yоur blog аnd hаvе mу friends check uр hеrе often.
Posted by: ( Email | Visit ) at 4/11/2015 1:35 AM

Thіs site іs excellent аnd ѕо іѕ hоw thе subject matter waѕ explained. You're іn point оf fact а juѕt rіght webmaster. Thе website loading speed іѕ amazing.
Posted by: ( Email | Visit ) at 4/11/2015 1:36 AM

I rеallу enjoyed thiѕ article, іt waѕ informative аnd helped open mу mind tо nеw possibilities. Thаt іs thе power оf thе internet, connecting people worlds аpart аnd allowing uѕ tо learn аnd grow together.
Posted by: ( Email | Visit ) at 4/11/2015 1:37 AM

thanks for his information
Posted by: ( Email | Visit ) at 4/13/2015 4:58 PM

thanks for his information
Posted by: ( Email | Visit ) at 4/14/2015 7:14 PM

rеallу enjoyed thiѕ article,and recommend some best replica watches for you
Posted by: ( Email | Visit ) at 4/23/2015 6:47 AM

Your use of our website constitutes your agreement to the terms of this privacy policy.
Posted by: ( Email | Visit ) at 5/10/2015 3:14 AM

implemented, not after it is criticized in the scientific or lay press - nor, we might have added

archtics ticketing system
Posted by: ( Email | Visit ) at 5/10/2015 4:03 AM

he Hastings Center maintains physical, electronic, and procedural safeguards to help guard your personal information. Personally identifiable nformation is transmitted .
delhi to jaipur taxi
Posted by: ( Email | Visit ) at 5/11/2015 1:51 AM

Cookies are also useful in tracking transaction histories and preserving information between sessions. The information collected from cookies may also be used to improve the functionality of our website...

graphic design studio
Posted by: ( Email | Visit ) at 5/11/2015 5:52 AM

Thіs site іs excellent аnd ѕо іѕ hоw the subject matter was explained. You're іn point оf fact а just rіght webmaster.

best help desk software
Posted by: ( Email | Visit ) at 5/12/2015 6:41 AM

I rеallу enjoyed this article, іt was informative аnd helped open mу mind tо nеw possibilities. Thаt іs the power оf the internet, connecting people worlds аpart аnd allowing uѕ tо learn аnd grow together.

Free Ebook Downloads
Posted by: ( Email | Visit ) at 5/14/2015 6:07 AM

When i contain the many information within such a site tactics. Source thank you commercials designed for
Marijuana news
Posted by: ( Email | Visit ) at 5/16/2015 5:47 AM

extensions were the top four hair no no’s for women over 50 and 35% of those polled accept that their hair was in its best condition
nutraceutical formula development
Posted by: ( Email | Visit ) at 5/17/2015 6:13 AM

Thank you for the great article I did enjoyed reading it, I want to encourage that you continue your great job, have a good day.
Posted by: ( Email | Visit ) at 5/17/2015 7:56 AM

There is a lot of information here that can help any business get started with a successful social networking campaign!
utah website development
Posted by: ( Email | Visit ) at 5/18/2015 2:21 AM

Thank you for the great article I did enjoyed reading it, I want to encourage that you continue your great job, have a good day.

Posted by: ( Email | Visit ) at 5/20/2015 6:22 AM

Thank you for the great article I did enjoyed reading it, I want to encourage that you continue your great job, have a good day.
unlocking cell phones
Posted by: ( Email | Visit ) at 5/21/2015 8:48 AM

There is a lot of information here that can help any business get started with a successful social networking campaign!
ward solicitors bristol
Posted by: ( Email | Visit ) at 5/21/2015 9:17 AM